D'ambrosio Claudio, Akin Cem, Wu Yalin, Magnusson Magnus K, Metcalfe Dean D
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD 20892-1881, USA.
J Allergy Clin Immunol. 2003 Dec;112(6):1162-70. doi: 10.1016/j.jaci.2003.07.008.
Mastocytosis is a rare clonal disorder that might be accompanied by non-mast-cell clonal hematologic disorders, such as myeloproliferative or myelodysplastic syndromes.
Our aim was to further understand the pathologic basis of mastocytosis and to identify novel molecular markers of disease.
Microarray analysis was performed on RNA preparations obtained from bone marrow mononuclear cells of patients with mastocytosis. Results were compared with gene expression profiles performed on bone marrow mononuclear cells of healthy subjects.
Analysis of gene expression in neoplastic bone marrow tissues revealed highly consistent profiles. One hundred four genes were significantly upregulated, and 64 genes were significantly downregulated in the bone marrow of patients with mastocytosis. The most prominent differentially expressed gene was alpha-tryptase (44.6-fold increase). Also upregulated were genes involved in cell proliferation, neoplastic transformation, and apoptosis. Both hierarchical and K-means clustering analyses identified an identical group of 10 genes highly coordinately overexpressed in patients with mastocytosis, including genes for the mast-cell-associated enzymes alpha- and beta-tryptase and carboxypeptidase A. The expression level of 3 of these 10 genes (alpha-tryptase, the activating transcription factor type 3, and the muscle aponeurotic fibrosarcoma type F oncogene) was significantly correlated with serum tryptase levels, a surrogate marker of disease.
The data presented in this study reveal significant differences in gene expression in the bone marrow of patients with mastocytosis compared with healthy subjects, demonstrate highly coordinated genes that might contribute to pathology, and identify 3 genes as candidate molecular markers for systemic disease.
肥大细胞增多症是一种罕见的克隆性疾病,可能伴有非肥大细胞克隆性血液系统疾病,如骨髓增殖性或骨髓增生异常综合征。
我们的目的是进一步了解肥大细胞增多症的病理基础,并确定该疾病的新型分子标志物。
对从肥大细胞增多症患者的骨髓单个核细胞中获得的RNA制剂进行微阵列分析。将结果与对健康受试者的骨髓单个核细胞进行的基因表达谱进行比较。
对肿瘤性骨髓组织中的基因表达分析显示出高度一致的谱。在肥大细胞增多症患者的骨髓中,104个基因显著上调,64个基因显著下调。最显著差异表达的基因是α-胰蛋白酶(增加44.6倍)。参与细胞增殖、肿瘤转化和凋亡的基因也上调。层次聚类分析和K均值聚类分析均确定了一组相同的10个基因,在肥大细胞增多症患者中高度协同过表达,包括与肥大细胞相关的酶α-和β-胰蛋白酶以及羧肽酶A的基因。这10个基因中的3个基因(α-胰蛋白酶、3型激活转录因子和F型肌肉腱膜纤维肉瘤癌基因)的表达水平与血清胰蛋白酶水平显著相关,血清胰蛋白酶水平是该疾病的一个替代标志物。
本研究提供的数据揭示了肥大细胞增多症患者骨髓中的基因表达与健康受试者相比存在显著差异,证明了可能导致病理改变的高度协同基因,并确定了3个基因作为全身性疾病的候选分子标志物。